drugset / Trial / NCT01644500

A Study Comparing the Effects and Safety of Dulaglutide With Glimepiride in Type 2 Diabetes Mellitus

NCT01644500

Phase 3 Completed 737 enrolled Eli Lilly and Company
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to examine if once-weekly dulaglutide is efficient and safe compared to glimepiride in participants with type 2 diabetes mellitus who have inadequate glycemic control with oral antihyperglycemic medication (OAM) or are OAM-naïve.

Timeline

Start
2012-07
Primary completion
2014-08
Completion
2014-08

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Dulaglutide Peptide 0.75 mg Subcutaneous
Subject Dulaglutide Peptide 1.5 mg Subcutaneous
Comparator Glimepiride Small molecule Oral